Reuters logo
BRIEF-Trial data demonstrate robust response rate with Indoximod in combination with Keytruda
April 4, 2017 / 1:15 PM / 6 months ago

BRIEF-Trial data demonstrate robust response rate with Indoximod in combination with Keytruda

April 4 (Reuters) - Newlink Genetics Corp

* Interim phase 2 data demonstrate robust response rate with Indoximod in combination with Keytruda for patients with advanced melanoma at AACR plenary

* Combination was generally well tolerated with low rates of grade 3 or higher adverse events

* Data report on cohort of 60 evaluable patients who received combination of Indoximod plus Pembrolizumab which demonstrated 52 pct ORR, 73 pct DCR

* Expect further clinical validation of IDO pathway as an immuno-oncology target throughout 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below